Novo Nordisk, the Danish pharmaceutical company behind Ozempic and Wegovy, received a rare “sell” rating from Deutsche Bank on Thursday. The downgrade comes after the company’s stock price dropped roughly 70% from its peak, according to the bank’s analysts.
Wall Street has largely maintained “hold” or “buy” recommendations on the stock despite its prolonged decline. Deutsche Bank’s move breaks that trend, signaling growing concerns over the company’s future growth prospects.
The stock’s slide reflects a broader reassessment of the weight-loss drug market. Competition has intensified, with rivals introducing new treatments that threaten Novo Nordisk’s market share.
The analyst note highlighted uncertainty around pricing pressures and the sustainability of demand. These factors have weighed on investor sentiment, pushing the stock to multi-year lows.
Novo Nordisk has not yet responded publicly to the downgrade. The company’s shares have struggled to recover as investors digest the shifting landscape.
Deutsche Bank’s action contrasts with the general caution among analysts, who have often shied away from outright sell calls. The new rating places Novo Nordisk in a small group of large-cap pharma stocks facing such a stance.
For investors, the downgrade adds another layer of risk to an already volatile situation. The company’s next earnings report will likely offer clearer signals on how it plans to navigate the challenges ahead.
